DOCSLIB.ORG

Summary Conflict of Interest Statements BCC 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary Conflict of Interest Statements BCC 2021 Summary conflict of interest statements BCC 2021 Last name First name Type of affiliation/ financial interest Name of commercial company Aapro Matti Receipt of grants/research supports: Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Rache, Sandoz, Tesaro, Teva, Vifor Receipt of honoraria or consultation fees: Accord Pharmaceuticals, Amgen, Astellas, Bayer HealthCare Pharmaceuticals (Schering), Biocon, Boehringer Ingelheim, BMS, Celgene, Cephalon, Chugai Pharmaceutical Co. Ltd., Clinigen Group, Dr.Reddy's Laboratories, Eisai Co. Ltd., Eli Lilly, Genomic Health (Exact Sciences), GlaxoSmithKline (GSK), Glenmark Pharmaceuticals Limited, Gl Therapeutics, lnc., Helsinn Healthcare SA, Hospira (Pfizer), lpsen, Janssen Biotech, Johnson & Johnson, Kyowa Kirin Group, Merck, Merck Serono (Merck KGaA), Mundipharma International Limited, Novartis, Pfizer, Pierre Fabre, Rache, Sandoz, Sanofi, Taiho Pharmaceutical, Tesaro (GSK), Teva Pharmaceutical lndustries Ltd., Vifor Pharma Other support: European Cancer Organisation, SPCC, Cancer Center Genolier Aebi Stephan Receipt of honoraria or consultation fees: Novartis, Roche, Pfizer Other support: Support for CME lectures of the Lucerne Cancer Center: Amgen, Astellas, Bayer, Bristol-Myers Squibb, Debiopharm International SA, Eisai, Ipsen Pharma, Janssen, Merck, MSD, Pfizer, Roche, Sanofi Genzyme, Servier, Takeda André Fabrice Receipt of grants/research supports: Comepensated to the hospital: Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly Barrios Carlos Receipt of grants/research supports: Abbvie, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, Covance, Lilly, Medivation, Merck Serono, Merck Sharp Dohme (MSD), Novartis, Pfizer, Pharma Mar, Roche/Genentech Receipt of honoraria or consultation fees: Boehringer-lngelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, MSD, Astra Zeneca, Bayer, Lilly Bergh Jonas Receipt of grants/research supports: Grant support for clinical studies with payments to Karolinska Inst and/or Karolinska Univ Hospital Other support: Co-author of a Chapter in UpToDate; prognostic and therapy predictive factors in Early Breast cancer, payments to Asklepios Medicin Hb Bonnefoi Herve Receipt of honoraria or consultation fees: Roche Other support: Travel expenses: Roche, Pfizer Bretel Morales Denisse Receipt of grants/research supports: Roche, MSD Brucker Sara Receipt of grants/research supports: Storz, Intuitive Receipt of honoraria or consultation fees: Roche, MSD, Teva, Olympus, Pfizer, Novartis, AstraZeneca Burstein Harald No potential conflict of interest to report Summary conflict of interest statements BCC 2021 Last name First name Type of affiliation/ financial interest Name of commercial company Cameron David Receipt of honoraria or consultation fees: By institution: MERCK Sharp Dohme Ltd., Clovis, Novartis Pharma, SeaGen (Seattle Genetics), Erytech Pharma Inc, G1 Therapeutics, Eli Lilly & Company, Daiichi Sankyo, Roche Products Ltd., RTI Health Solutions, PRIMA BioMed Ltd., Eisai, Astrazeneca, Pfizer, Synton, Puma, Zymeworks, Celgene, Samsung Bioepsis, European Cancer Organisation, Succint Medical Communications, Oncolytics Biotech (U.S) Inc, Celldex Therapeutics Inc, San Antonio Breast Cancer Consortium, Highfield Communication Cardoso Fatima Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prlME Oncology, Roche, Samsung Bioepis, Sanofi, Seattle Genetics, Teva Carey Lisa Receipt of honoraria or consultation fees: Seattle Genetics, Novartis - Dr. Carey does not have any signatory authority over any UNC account receiving these contracted monies Cescon Dave Receipt of grants/research supports: GlaxoSmithKline, Pfizer, Roche Receipt of honoraria or consultation fees: Agendia, AstraZeneca, Dynamo Therapeutics, Exact Sciences, GlaxoSmithKline, Merck, Novartis, Pfizer, Puma, Roche Other support: Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene Chua Boon Receipt of grants/research supports: NanoString: provision of Prosigna kit for clinical trial Ciruelos Eva Receipt of honoraria or consultation fees: Lilly, Pfizer, Roche, AstraZeneca, Novartis Participation in a company sponsored speaker's bureau: Lilly, Pfizer, Roche Coates Alan No potential conflict of interest to report Colleoni Marco Receipt of honoraria or consultation fees: Novartis Cortes Javier Receipt of honoraria or consultation fees: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck, Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Novartis, Eisai, Pfizer, Samsung Bioepis Stock shareholder: MedSIR Other support: Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London Travel, accommodation, expenses: Roche, Novartis, Eisai, pfizer, Daiichi Sankyo Summary conflict of interest statements BCC 2021 Last name First name Type of affiliation/ financial interest Name of commercial company Curigliano Giuseppe Receipt of honoraria or consultation fees: Roche, Pfizer, Astra Zeneca, Daichii Sankyo, BMS Delaloge Suzette Receipt of grants/research supports: To the institution: Pfizer, Roche, Novartis, Sanofi, Merck, Puma, Lilly, AstraZeneca, Orion, Daiichi Sankyo Denkert Carsten Receipt of grants/research supports: Myriad Genetics Receipt of honoraria or consultation fees: Novartis, Roche, MSD, Daiichi Sankyo Stock shareholder: Sividon Diagnostics (Myriad) Dubsky Peter Receipt of grants/research supports: Agendia, Cepheid/Danaher, OncoMark, Myriad (all via ABCSG) Receipt of honoraria or consultation fees: Amgen, Pfizer, Rache, Astra Zeneca (all to Hirslanden Klinik St. Anna) Other support: Travel support: Roche Ejlertsen Bent Receipt of grants/research supports: NanoString Technologies, Oncology Venture, Roche, Novartis Fitzal Florian Receipt of grants/research supports: NanoString Technologies, Pfizer, Novartis, Roche Receipt of honoraria or consultation fees: Lilly, Pfizer, Novartis, Roche, AstraZeneca, Bondimed Francis Prudence Others: Travel to lectures overseas: Novartis, Ipsen Galimberti Viviana No potential conflict of interest to report Gamal El Din Mohamed MHebatallah No potential conflict of interest to report Garber Judy Receipt of grants/research supports: Myriad Genetics, Ambry Genetics, Invitae Genetics, AstraZeneca Receipt of honoraria or consultation fees: Helix Genetics Other support: Editorial Services publications; President, Fellows of the AACR Academy; member, Foundation Board of the AACR: American Association for Cancer Research Co-Scientific Director: Breast Cancer Research Foundation Board of Directors: Facing Our Risk of Cancer Empowered Spouse/partner: Consulting: Novartis, GTx Pharmaceuticals, Aleta BioTherapeutics, H3 Biomedicine Inc. / Scientific Advisory Board: Oric Pharmaceuticals, Kronos Bio, Susan G. Komen for the Cure, James P. Wilmot Foundation, Inc, Diane Helis Henry Medical Research Foundation, Adrienne Helis Melvin Medical Research Foundation, Global Biological Standards Institute Giordano Sharon No potential conflict of interest to report Gnant Michael Receipt of honoraria or consultation fees: Amgen, DaiichiSankyo, EliLilly, Medison Pharma, LifeBrain, Nanostring, Novartis, TLC Biopharmaceuticals Spouse/partner: An immediate family member is employed by Sandoz Gradishar William Receipt of honoraria or consultation fees: DMC- Seattle genetics, Advisory board- Genentech, immunomedics, astra-zenenca, Daiichi Other support: Sponsored clinical research: Roche, Genentech Summary conflict of interest statements BCC 2021 Last name First name Type of affiliation/ financial interest Name of commercial company Gulluoglu Bahadir Receipt of honoraria or consultation fees: Roche Harbeck Nadia Receipt of honoraria or consultation fees: Astra Zeneca, Daiichi-Sankyo, Lilly, MSO, Novartis, Pierre Fabre, Pfizer, Roche, Seattle Genetics Participation in a company sponsored speaker's bureau: Astra Zeneca, Daiichi-Sankyo, Lilly, MSO, Novartis, Pierre Fabre, Pfizer, Roche, Seattle Genetics Stock shareholder: Minority ownership WSG (West German Study Group) Spouse/partner: Consulting WSG (West German Studay Group) Heil Jörg No potential conflict of interest to report Huang Chiun-Sheng Receipt of grants/research supports: Astra Zeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, OBI, Pfizer, Roche Receipt of honoraria or consultation fees: Amgen, Astra Zeneca, Daiichi Sankyo, Eli Lilly, Pfizer, Roche Participation in a company sponsored speaker's bureau: Astra Zeneca, Eli Lilly, Novartis, Pfizer, Roche Other support: Travel expenses: Roche, AstraZeneca Huober Jens Receipt of grants/research supports: Celgene, Novartis, Hexal Receipt of honoraria or consultation fees: Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Eisai Other support: Travel expenses: Roche, Pfizer, Novartis, Celgene, Daiichi Ilbawi Andre No potential conflict of interest to report Jiang Zefei No potential conflict of interest to report Johnston Steven Receipt of grants/research supports: Funding to Institution:
Load more

Recommended publications
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • Cereblon and Its Downstream Substrates As Molecular Targets of Immunomodulatory Drugs
    Int J Hematol (2016) 104:293–299 DOI 10.1007/s12185-016-2073-4 PROGRESS IN HEMATOLOGY Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs Takumi Ito1,2 · Hiroshi Handa1 Received: 15 June 2016 / Revised: 19 July 2016 / Accepted: 19 July 2016 / Published online: 26 July 2016 © The Japanese Society of Hematology 2016 Abstract Thalidomide was first developed as a sedative History of immunomodulatory drugs (IMiDs) around 60 years ago, but exhibited teratogenicity, leading to serious defects such as limb deformities. Nevertheless, Immunomodulatory drugs (IMiDs) are a new class of anti- thalidomide is now recognized as a therapeutic drug for the cancer drugs for which the parent molecule is thalidomide. treatment of Hansen’s disease and myeloma. Immunomod- Thalidomide (Fig. 1) was developed as a sedative in 1950s ulatory drugs (IMiDs), a new class of anti-cancer drug by the German pharmaceutical company Grunenthal. derived from thalidomide, have also been developed and Experiments using rodents initially suggested it to be safe exert potent anti-cancer effects. Although the molecular for use in humans, and the drug was sold over 40 countries, mechanism of thalidomide and IMiDs remained unclear for including Japan. However, as is widely known, thalidomide a long time, cereblon, a substrate receptor of the CRL4 E3 was found to have serious teratogenic effects. Use during ubiquitin ligase was identified as a primary direct target by pregnancy is associated with developmental defects of the a new affinity technique. A growing body of evidence sug- limbs and ears.
    [Show full text]
  • Characterization of Ocular Adverse Events in Patients Receiving
    Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafadotin for ≥12 Months: Post-Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma S. LONIAL1; A.K. NOOKA1; P. THULASI2; A.Z. BADROS3; B.H. JENG3; N.S. CALLANDER4; D. SBOROV5; B.E. ZAUGG6; R. POPAT7; S. DEGLI ESPOSTI8; J. BARON9; A. DOHERTY9; E. LEWIS10; J. OPALINSKA9; P. PAKA9; T. PIONTEK9; I. GUPTA9; A.V. FAROOQ11; A. JAKUBOWIAK11 | 1Emory University, Winship Cancer Institute, Atlanta, GA, USA; 2Emory Eye Center, Emory University, Atlanta, GA, USA; 3University of Maryland School of Medicine, Baltimore, MD, USA; 4University of Wisconsin, Carbone Cancer Center, Madison, WI, USA; 5Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 6Moran Eye Center, University of Utah, Salt Lake City, UT, USA; 7University College London Hospitals, NHS Foundation Trust, London, UK; 8NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 9GlaxoSmithKline, Collegeville, PA, USA; 10GlaxoSmithKline, Research Triangle Park, NC, USA; 11University of Chicago Medical Center, Chicago, IL, USA Dose delays and reductions related to ocular adverse events INTRODUCTION RESULTS All 14 patients required ≥2 dose delays, with dose reduction (to 1.92 mg/kg) in CONCLUSIONS Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class, monomethyl auristatin F (MMAF)-containing 12 patients (86%). Demographics, efficacy, and overall safety information for patients treated with belamaf In this subset of 14 patients from the DREAMM-2 study, the median duration of response was antibody–drug conjugate (ADC) that binds to B-cell maturation antigen (BCMA) and eliminates multiple myeloma cells by for ≥12 months ● Patients experienced a mean of 3.6 dose delays over the ≥12 months of treatment a multimodal mechanism of action.1 (median: 3.5, range: 2–6).
    [Show full text]
  • AMGEN INC. V. SANOFI
    Case: 20-1074 Document: 159 Page: 1 Filed: 06/21/2021 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ AMGEN INC., AMGEN MANUFACTURING, LIMITED, AMGEN USA, INC., Plaintiffs-Appellants v. SANOFI, AVENTISUB LLC, FKA AVENTIS PHARMACEUTICALS INC., REGENERON PHARMACEUTICALS INC., SANOFI-AVENTIS U.S. LLC, Defendants-Appellees ______________________ 2020-1074 ______________________ Appeal from the United States District Court for the District of Delaware in Nos. 1:14-cv-01317-RGA, 1:14-cv- 01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA, Judge Richard G. Andrews. ______________________ JEFFREY A. LAMKEN, MoloLamken LLP, Washington, DC, filed a petition for rehearing en banc for plaintiffs-ap- pellants. Also represented by SARAH JUSTINE NEWMAN, MICHAEL GREGORY PATTILLO, JR.; SARA MARGOLIS, New York, NY; EMILY JOHNSON, ERICA S. OLSON, STEVEN TANG, STUART WATT, WENDY A. WHITEFORD, Amgen Inc., Thou- sand Oaks, CA; KEITH HUMMEL, Cravath Swaine & Moore LLP, New York, NY; WILLIAM G. GAEDE, III, McDermott Case: 20-1074 Document: 159 Page: 2 Filed: 06/21/2021 2 AMGEN INC. v. SANOFI Will & Emery LLP, Menlo Park, CA; CHRISTOPHER B. MEAD, Schertler Onorato Mead & Sears LLP, Washington, DC; JAMES L. HIGGINS, MELANIE K. SHARP, Young, Cona- way, Stargatt & Taylor, LLP, Wilmington, DE. Plaintiff- appellant Amgen Inc. also represented by SARAH CHAPIN COLUMBIA, McDermott, Will & Emery LLP, Boston, MA; LAUREN MARTIN, Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA. MATTHEW WOLF, Arnold & Porter Kaye Scholer LLP, Washington, DC, filed a response for defendants-appellees. Also represented by VICTORIA REINES; DAVID K. BARR, DANIEL REISNER, New York, NY; DEBORAH E.
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • Critical Analysis of Valuation and Strategical Orientation of Merger
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018 https://doi.org/10.1080/14737167.2018.1417040 REVIEW Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry Raphaela Marie Louisa Dierks, Olivier Bruyère and Jean-Yves Reginster Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics, CHU Sart-Tilman, Liège, Belgium ABSTRACT ARTICLE HISTORY Introduction: The pharmaceutical industry is undergoing major shifts due to changing macro and Received 21 October 2017 micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on Accepted 11 December 2017 generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses KEYWORDS two completed deals in 2016 above 1bn USD. Thereafter one outlines the main motives behind M&A Pharmaceutical industry; deals and concluded by discussing whether M&A harms medical innovations. merger and acquisitions Areas covered: The paper is based on empirical study questioning existing literature in order to (M&A); valuation; inorganic critically analyse valuation and the strategical orientation of pharmaceutical companies growth; medical innovation; Expert commentary: Pharmaceutical companies understand the changing market conditions and non-core assets; drug favour their expertise. The restructuring of the industry moves to small niche companies (I.e. pipeline; tax inversion Biopharma or biotech companies) researching key innovations and big companies purchasing them to develop them, create clinical trials and distribute them as this is a costly manner Conclusion: One can expect more M&A deals during the next years focusing on value rather than volume. Pharmaceutical players resilient to the market changes may survive if they change their business model from a traditional vertical one to outsourcing and diversification including external players.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2019 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. - 1 - [Translation] To Our Shareholders At the Daiichi Sankyo Group (“the Group”), we are proceeding with the initiatives of 4th mid- term business plan with the aim of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as set forth in our 2025 Vision. In fiscal 2018, we made significant progress in developing new drugs in oncology area, including DS-8201, an antibody drug conjugates utilizing our proprietary technologies. In addition, we entered into a strategic collaboration agreement with AstraZeneca, which has strengths in the oncology business, for the global development and commercialization of DS-8201 in order to maximize its value. Furthermore, sales of mainstay products such as edoxaban, an anticoagulant which supports current earnings of the Group, were firm in Japan and overseas. The achievement of initial target of mid-term business plan for fiscal 2020 is expected to be delayed by two years due to failure of achievement of the plan for pain franchise business and additional investments in research and development. However, we are gaining confidence of achieving our 2025 Vision and accelerating growth in the future due to the significant improvement in the value of oncology area pipelines. We will continue to make every effort to achieve the goals of the Medium-Term Management Plan and 2025 Vision. I greatly appreciate your continued support in the future.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2019
    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
    [Show full text]
  • Convocation Notice of the 16Th Ordinary General Meeting of Shareholders
    [Translation] CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2021 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. [Translation] To Our Shareholders We sincerely appreciate the continuous kindness of our shareholders. In addition, we would like to express our deepest sympathies to those who passed away due to COVID-19, and thank the medical personnel who are close to those who are fighting illness and are making efforts in treatment. We will continue to devote ourselves to the research and development of vaccines and therapeutic agents. Our “Purpose” is to “contribute to the enrichment of quality of life around the world.” As a pharmaceutical company with strengths in science and technology, we continuously create innovative pharmaceuticals and provide pharmaceuticals that meet diverse medical needs to provide sustainable value to society. We were able to launch the anti-cancer drug “Enhertu”, which is an antibody-drug conjugate (ADC) that utilizes our unique technology, in Japan and Europe in fiscal 2020, following the launch in the U.S. in fiscal 2019. Subsequent ADCs such as Dato-DXd and HER3-DXd are also steadily developing. Now, we have newly established our 2030 Vision of being an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society,” and have established 5-Year Business Plan (fiscal 2021 to fiscal 2025) as a plan to realize our 2025 Vision, “Global Pharma Innovator with Competitive Advantage in Oncology.” By working together as a Daiichi Sankyo Group on 5-Year Business Plan toward the 2030 Vision, we aim to solve the social issues expected of our company and increase shareholder value.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - [Translation] (Securities Identification Code 4568) May 31, 2011 To Shareholders, Daiichi Sankyo Company, Limited Joji Nakayama, Representative Director and President & CEO 5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo, Japan CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS We wish to extend our deepest sympathy to all those who have suffered hardship from the Great East Japan Earthquake that occurred in March 2011. Daiichi Sankyo Company, Limited (“the Company”) respectfully requests your attendance at the 6th Ordinary General Meeting of Shareholders (“the Meeting”), which will be held as detailed below. If you will not be able to attend the Meeting, you may exercise your voting rights through either of the methods described below, in which case we ask that you please exercise your voting rights by 17:30 (within our business hours), Friday, June 24, 2011 (Japan Time), after examining the attached reference documents. [Exercise of Voting Rights by Mail] Please indicate your approval or disapproval for the proposals on the enclosed voting form and return the form to the Company. Please note that the form must be received by the Company no later than the above-mentioned deadline. [Exercise of Voting Rights on the Internet etc.] After examining “Information on Exercise of Voting Rights, etc.” on pages 57 and 58, please vote on the Internet at the dedicated voting website (http://www.evote.jp/) no later than the above-mentioned deadline. The Company is participating in the platform for electronic exercise of voting rights for institutional investors operated by ICJ Inc.
    [Show full text]
  • Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
    cancers Review Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma Fatih M. Uckun 1,2,3 1 Norris Comprehensive Cancer Center and Childrens Center for Cancer and Blood Diseases, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, CA 90027, USA; [email protected] 2 Department of Developmental Therapeutics, Immunology, and Integrative Medicine, Drug Discovery Institute, Ares Pharmaceuticals, St. Paul, MN 55110, USA 3 Reven Pharmaceuticals, Translational Oncology Program, Golden, CO 80401, USA Simple Summary: This article provides a comprehensive review of new and emerging treatment strategies against multiple myeloma that employ precision medicines and/or drugs capable of improving the ability of the immune system to prevent or slow down the progression of multiple myeloma. These rationally designed new treatment methods have the potential to change the therapeutic landscape in multiple myeloma and improve the long-term survival outcome. Abstract: SeverFigurel cellular elements of the bone marrow (BM) microenvironment in multiple myeloma (MM) patients contribute to the immune evasion, proliferation, and drug resistance of MM cells, including myeloid-derived suppressor cells (MDSCs), tumor-associated M2-like, “alter- natively activated” macrophages, CD38+ regulatory B-cells (Bregs), and regulatory T-cells (Tregs). These immunosuppressive elements in bidirectional and multi-directional crosstalk with each other inhibit both memory and cytotoxic effector T-cell populations as well as natural killer (NK) cells. Immunomodulatory imide drugs (IMiDs), protease inhibitors (PI), monoclonal antibodies (MoAb), Citation: Uckun, F.M. Overcoming the Immunosuppressive Tumor adoptive T-cell/NK cell therapy, and inhibitors of anti-apoptotic signaling pathways have emerged as Microenvironment in Multiple promising therapeutic platforms that can be employed in various combinations as part of a rationally Myeloma.
    [Show full text]
  • 【Research Report】The GR Scores 2018
    Nikko Research Review Research Report Aug. 2019 The GR Scores 2018 Institute of Social System Research Megumi Terayama Yasuyuki Sugiura Abstract Nikko Research Center, Inc. has developed the Governance Research Scores (GR scores), which evaluate the strength of corporate governance in Japanese companies. We list the GR Scores of 100 Is major domestic companies by benchmarking their practices against Japan’s Corporate Governance Code as the domestic standard, and the ICGN Global Governance Principles as the global standard. Here, we report the GR Scores 2018 as of December 31, 2017 in sequential form. The overall domestic average score rose 3.1 points to 51.6% from the previous year. Sixty-nine companies had higher domestic scores, and only eight companies had lower scores, compared with the previous year. Disclosing the result of board evaluations, conducting effective board meetings, and setting targets such as earnings in the medium-term management plan seemed to drive this improvement in scores. The overall global average score also rose 1.4 points to 22.3% from the previous year; however, it remains low. While 63 companies had higher global scores, 25 companies had lower scores compared with the previous year. The main reasons for the rise include easing of the requirement of independence for controlled companies by ICGN in their revised principles and a certain number of companies adopting restricted stock for management compensation. By contrast, a tightening of the independence requirement for the audit committee lowered the global scores. Table of Contents 1. Introduction 2. Outline of the GR Scores 2018 2.1 Evaluation method 2.2 Revision of evaluation items from the GR Scores 2017 3.
    [Show full text]